Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-07-07T17:05:56.767Z Has data issue: false hasContentIssue false

1 - The clinical management of hepatic neoplasms

Published online by Cambridge University Press:  23 December 2009

By
Daniel Palmer  and
Philip Johnson
Edited by
Andy Adam  and
Peter R. Mueller
Andy Adam
Affiliation:
University of London
Peter R. Mueller
Affiliation:
Massachussets General Hospital, Boston
Get access

Summary

Introduction

The liver is the organ most frequently involved by cancer. In developing countries hepatocellular carcinoma is a major public health problem responsible for over 500 000 deaths per year. In the West its incidence is rising, in part due to the increasing prevalence of chronic hepatitis C virus infection. The liver is also the commonest site of metastases, and up to 75% of primary tumors drained by the portal venous system involve the liver before death.

This chapter will review the epidemiology, etiology, and current management of hepatocellular carcinoma and of secondary liver cancer, with particular reference to colorectal metastases as a paradigm for the multidisciplinary management of cancer.

Hepatocellular carcinoma

Epidemiology and etiology

Hepatocellular carcinoma (HCC) is one of the commonest malignancies worldwide but with wide geographical variation, the highest incidence occurring in sub-Saharan Africa and the Far East. This variation suggests the importance of environmental factors (Table 1.1). Prime among these are chronic infection by hepatitis viruses B and C (HBV and HCV) and exposure to aflatoxin. In a study of 22 000 Chinese males, 15% of whom were HBV carriers, the relative risk for HCC development in HBV-positive men was 98.4. An HBV vaccination program, inoculating neonates, was initiated in Taiwan in the early 1980s and has resulted in a clear reduction in the incidence of childhood HCC. However, an effect on the incidence of HCC in adults may take a further 20 years to become apparent.

Type
Chapter
Information
Interventional Radiological Treatment of Liver Tumors , pp. 1 - 24
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Parkin, DM, Bray, F, Ferlay, J, Pisani, P.Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.CrossRefGoogle ScholarPubMed
El-Serag, HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87–107.CrossRefGoogle ScholarPubMed
El-Serag, HB, Mason, AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50.CrossRefGoogle ScholarPubMed
Johnson, PJ. Risk factors for hepatocellular carcinoma. ASCO 42nd Annual Meeting Educational Book 2006, 234–7.Google Scholar
Chang, MH, Chen, CJ, Lai, MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855–9.CrossRefGoogle ScholarPubMed
Chan, HL, Tse, CH, Mo, F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177–82.CrossRefGoogle ScholarPubMed
Liaw, YF, Sung, JJ, Chow, WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–31.CrossRefGoogle ScholarPubMed
Sun, CA, Wu, DM, Lin, CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003; 157: 674–82.CrossRefGoogle ScholarPubMed
Yu, ML, Lin, SM, Chuang, WL, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985–94.Google ScholarPubMed
Bruno, S, Crosignani, A, Maisonneuve, P, et al. Hepatitis C virus genotype 1B as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350–6.CrossRefGoogle ScholarPubMed
Johnson, PJ, Williams, R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987; 4: 140–7.CrossRefGoogle ScholarPubMed
Kensler, TW, Egner, PA, Wang, JB, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 2004; 127 (5 Suppl 1): S310–18.CrossRefGoogle ScholarPubMed
Turner, PC, Sylla, A, Gong, YY, et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet 2005; 365: 1950–6.CrossRefGoogle ScholarPubMed
Lai, EC, Lau, WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006; 141: 191–8.CrossRefGoogle ScholarPubMed
McFadzean, AJ, Todd, D, Tso, SC. Erythrocytosis associated with hepatocellular carcinoma. Blood 1967; 29: 808–11.Google ScholarPubMed
Bruix, J, Sherman, M, Llovet, JM, et al. EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421–30.CrossRefGoogle ScholarPubMed
Bhattacharjya, S, Bhattacharjya, T, Quaglia, A, et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig Surg 2004; 21: 152–9.CrossRefGoogle ScholarPubMed
Johnson, PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145–59.CrossRefGoogle ScholarPubMed
Okuda, K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002; 17: 401–5.CrossRefGoogle ScholarPubMed
Chen, JG, Parkin, DM, Chen, QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204–9.CrossRefGoogle ScholarPubMed
Bruix, J, Sherman, M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36.CrossRefGoogle Scholar
Sherman, M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143–54.CrossRefGoogle ScholarPubMed
Thompson Coon, J, Rogers, G, Hewson, P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11: 1–206.CrossRefGoogle ScholarPubMed
Palmer, DH, Johnson, PJ. Hepatocellular carcinoma. In: Gospodarowicz, MK, O'Sullivan, B, Sobin, LH, eds. Prognostic Factors in Cancer, 3rd edn. Hoboken, NJ: Wiley, 2006, 143–6.Google Scholar
Ebara, M, Ohto, M, Shinagawa, T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis: a study in 22 patients. Gastroenterology 1986; 90: 289–98.CrossRefGoogle ScholarPubMed
Wayne, JD, Lauwers, GY, Ikai, I, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002; 235: 722–30.CrossRefGoogle ScholarPubMed
Poon, RT, Ng, IO, Fan, ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001; 19: 3037–44.CrossRefGoogle ScholarPubMed
Farmer, DG, Rosove, MH, Shaket, A, et al. Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219: 236–47.CrossRefGoogle ScholarPubMed
Vauthey, JN, Klimstra, D, Franceschi, D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169: 28–34.CrossRefGoogle ScholarPubMed
Mazzaferro, V, Regalia, E, Doci, R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9.CrossRefGoogle ScholarPubMed
Yao, FY, Ferrell, L, Bass, NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394–403.CrossRefGoogle Scholar
Yao, FY, Bass, NM, Nikolai, B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684–92.CrossRefGoogle ScholarPubMed
,United Network for Organ Sharing. www.unos.org.
Gondolesi, GE, Roayaie, S, Munoz, L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004; 239: 42–9.CrossRefGoogle ScholarPubMed
Palmer, DH, Johnson, PJ. Pre-operative locoregional therapy and liver transplantation for hepatocellular carcinoma (HCC): time for a randomised controlled trial. Am J Transplant 2005; 5: 641–2.CrossRefGoogle Scholar
Livraghi, T, Giorgio, A, Marin, G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101–8.CrossRefGoogle ScholarPubMed
Shiina, S, Teratani, T, Obi, S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 2005; 129: 122–30.CrossRefGoogle ScholarPubMed
Lencioni, R, Cioni, C, Crocetti, L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 961–7.CrossRefGoogle ScholarPubMed
Livraghi, T, Goldberg, SN, Lazzaroni, S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655–61.CrossRefGoogle ScholarPubMed
Chen, HS, Gross, JF. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 1980; 64: 31–40.Google ScholarPubMed
Yumoto, Y, Jinno, K, Tokuyama, K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985; 154: 19–24.CrossRefGoogle ScholarPubMed
Brown, DB, Geschwind, JF, Soulen, MC, et al. Society of Interventional Radiology position statement on chemoembolization for hepatic malignancies. J Vasc Intervent Radiol 2006; 17: 217–23.CrossRefGoogle ScholarPubMed
Lo, CM, Ngan, H, Tso, WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71.CrossRefGoogle ScholarPubMed
Llovet, JM, Real, MI, Montana, X, et al. Barcelona Clinic Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734–9.CrossRefGoogle ScholarPubMed
Bruix, J, Sala, M, Llovet, JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179–88.CrossRefGoogle ScholarPubMed
Simonetti, RG, Leberati, A, Angiolini, C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117–36.CrossRefGoogle ScholarPubMed
Palmer, DH, Hussain, SA, Johnson, PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 3: 1555–68.CrossRefGoogle Scholar
Gish, RG, Porta, C, Lazar, L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25: 3069–75.CrossRefGoogle ScholarPubMed
Yeo, W, Mok, TS, Zee, B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Nat Cancer Inst 2005; 97: 1532–8.CrossRefGoogle ScholarPubMed
Barbare, JC, Bouche, O, Bonnetain, F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23: 4338–46.CrossRefGoogle ScholarPubMed
,CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998; 352: 17–20.CrossRefGoogle Scholar
Reynaert, H, Rombouts, K, Vandermonde, A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53: 1180–9.CrossRefGoogle ScholarPubMed
Blaker, M, Schmitz, M, Gocht, A, et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004; 41: 112–18.CrossRefGoogle ScholarPubMed
Kouroumalis, E, Skordilis, P, Thermos, K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442–7.CrossRefGoogle ScholarPubMed
Yuen, MF, Poon, RT, Lai, CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36: 687–91.CrossRefGoogle ScholarPubMed
Becker, G, Allgaier, HP, Olschewski, M, et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9–15.CrossRefGoogle ScholarPubMed
Yamaguchi, R, Yano, H, Iemura, A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68–77.CrossRefGoogle ScholarPubMed
Chao, Y, Li, CP, Chau, GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355–62.CrossRefGoogle ScholarPubMed
Ito, Y, Sasaki, Y, Horimoto, M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27: 951–8.CrossRefGoogle ScholarPubMed
Abou-Alfa, GK, Schwartz, L, Ricci, S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293–300.CrossRefGoogle ScholarPubMed
Llovet, J, Ricci, S, Mazzaferro, V, et al. SHARP Investigators Study Group. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25. ASCO Annual Meeting Proceedings LBA1.Google Scholar
Zhu, AX, Sahani, DV, di Tomaso, E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007; 25: 4637.Google Scholar
Schwartz, J, Schwartz, M, Lehrer, D, et al. Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastases and without portal vein invasion. J Clin Oncol 2005; 23: 4122.CrossRefGoogle Scholar
Abbruzzese, JL, Thomas, MB. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093–108.Google Scholar
Philip, PA, Mahoney, MR, Allmer, C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657–63.CrossRefGoogle ScholarPubMed
Thomas, MB, Dutta, D, Brown, T, et al. A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2005; 23: 4083a.Google Scholar
Thomas, MB, Chadha, R, Iwasaki, M, et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25: 4567.Google Scholar
Abou-Alfa, G, Johnson, P, Knox, J, et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer 2007; 5 (Suppl): Abst 3500.Google Scholar
Hawkins, MA, Dawson, . Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006; 106: 1653–63.CrossRefGoogle Scholar
Robertson, JM, Lawrence, TS, Dworzanin, LM, et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 1993; 1: 1286–93.CrossRefGoogle Scholar
Raoul, JI, Bretagne, JF, Caucanas, JP, et al. Internal radiation therapy for hepatocellular carcinoma: results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer 1992; 69: 346–52.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Lau, WY, Ho, S, Leung, TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40: 583–92.CrossRefGoogle ScholarPubMed
Bhattacharjya, S, Bhattacharjya, T, Baber, S, et al. Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 2004; 91: 1361–9.CrossRefGoogle ScholarPubMed
Wagner, JS, Adson, MA, Heerden, JA, et al. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg 1984; 199: 502–8.CrossRefGoogle ScholarPubMed
Simmonds, PC, Primrose, JN, Colquitt, JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94: 982–99.CrossRefGoogle ScholarPubMed
Oshowo, A, Gillams, A, Harrison, E, et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90: 1240–3.CrossRefGoogle ScholarPubMed
,The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–75.CrossRefGoogle Scholar
Cutsem, E, Twelves, C, Cassidy, J, et al. Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097–106.CrossRefGoogle Scholar
Cunningham, D, Pyrhonen, S, James, RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–8.CrossRefGoogle ScholarPubMed
Saltz, LB, Cox, JV, Blanke, C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905–14.CrossRefGoogle ScholarPubMed
Douillard, JY, Cunningham, D, Roth, AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7.CrossRefGoogle ScholarPubMed
Rothenberg, ML, Meropol, NJ, Poplin, EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2002; 20: 1145–6.Google Scholar
Gramont, A, Vignoud, J, Tournigand, C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214–19.CrossRefGoogle ScholarPubMed
Gramont, A, Figer, A, Seymour, M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47.CrossRefGoogle ScholarPubMed
Goldberg, RM, Sargent, DJ, Morton, RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23–30.CrossRefGoogle ScholarPubMed
Tournigand, C, Andre, T, Achille, E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229–37.CrossRefGoogle ScholarPubMed
Kelly, H, Goldberg, RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553–60.CrossRefGoogle ScholarPubMed
Hurwitz, HI, Fehrenbacher, L, Novotny, W, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502–8.CrossRefGoogle ScholarPubMed
Kabbinavar, FF, Schulz, J, McCleod, M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705.CrossRefGoogle ScholarPubMed
Jain, RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.CrossRefGoogle ScholarPubMed
Cunningham, D, Humblet, Y, Siena, S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.CrossRefGoogle ScholarPubMed
Cutsem, E, Nowacki, M, Lang, I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25 (18S): 4000.Google Scholar
Roock, W, Piessevaux, H, Schutter, J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508–15.CrossRefGoogle ScholarPubMed
Leonard, GD, Brenner, B, Kemeny, NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038–48.CrossRefGoogle ScholarPubMed
Nordlinger, N, Sorbye, H, Collette, L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007; 25 (18S): LBA5.Google Scholar
Kemeny, NE, Niedzwiecki, D, Hollis, DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395–403.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×